InterCure Ltd (INCR) FinancialsINCRInterCure Ltd

InterCure Ltd (INCR) generates its revenue primarily from Cannabis Segment, which accounts for 100.0% of total sales, equivalent to ILS 106.17M. Understanding this concentration is critical for investors evaluating how INCR navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, InterCure Ltd maintains a gross margin of 0.34%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23.51%, while the net margin is -24.26%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively INCR converts its operational activities into shareholder value.

In the context of the broader market, INCR competes directly with industry leaders such as FOCL and STIM. With a market capitalization of $50.40M, it holds a significant position in the sector. When comparing efficiency, INCR's gross margin of 0.34% stands against FOCL's 55.58% and STIM's 52.17%. Such benchmarking helps identify whether InterCure Ltd is trading at a premium or discount relative to its financial performance.

InterCure has shown declining revenue and profitability, with a gross margin of only 0.34% in Q3 2025 and a net income loss of 17,003,000 ILS. The current ratio has decreased to 1.48, indicating potential liquidity issues.